Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 5 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 22 patents granted in the last 365 days
Quest Diagnostics Investments LLC is currently managing 7 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 7 pending office actions are distributed among 7 distinct examiners, which indicates that each active case is being evaluated by a different individual. This distribution means that the company prosecution experience is not concentrated under 1 official.
The busiest examiner for this portfolio is FRITCHMAN, REBECCA M, who is responsible for 1 pending office action. Since the total of 7 pending office actions is spread across 7 distinct examiners, FRITCHMAN, REBECCA M handles a portion of the workload that is equal to the other examiners involved. This creates a decentralized prosecution environment where the company must address the specific feedback of 7 different people.
The involvement of 5 distinct art units means that the technical review is conducted across different specialized groups at the patent office. With 7 distinct examiners and 5 distinct art units, the company must navigate various procedural preferences and technical standards. The company must tailor its responses to the specific requirements of the 5 distinct art units involved in the prosecution of these cases.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (14%) |
| §103 only | 4 (57%) |
| §112 only | 1 (14%) |
| Double-patenting + other | 1 (14%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FRITCHMAN, REBECCA M | 1 | 45.7% | +35.3% |
| SINGH, SATYENDRA K | 1 | 61.5% | +67.7% |
| WOOLWINE, SAMUEL C | 1 | 61.0% | +20.4% |
| CHEONG, CHEOM-GIL | 1 | 64.2% | +52.6% |
| BERTAGNA, ANGELA MARIE | 1 | 44.7% | +46.3% |
| IVICH, FERNANDO NMN | 1 | 48.7% | +69.8% |
| SITTON, JEHANNE SOUAYA | 1 | 53.2% | +48.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17610044 | MULTIPLEX ASSAY FOR DETERMINING THE ß-AMYLOID 42/40 RATIO IN HUMAN PLASMA SPECIMENS | IVICH, FERNANDO NMN | 22d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17610044 | MULTIPLEX ASSAY FOR DETERMINING THE ß-AMYLOID 42/40 RATIO IN HUMAN PLASMA SPECIMENS | IVICH, FERNANDO NMN | 22d overdue |
| 17986339 | BORDETELLA DETECTION ASSAY | BERTAGNA, ANGELA MARIE | 20d |
| 19462819 | MASS SPECTROMETRY OF STEROIDAL COMPOUNDS IN MULTIPLEX SAMPLES | FRITCHMAN, REBECCA M | — |
| 18884490 | MASS SPECTROMETRY METHOD FOR MEASURING THIAMINE IN BODY FLUID | SINGH, SATYENDRA K | — |
| 18794356 | METHODS FOR THE DIAGNOSIS OF BACTERIAL VAGINOSIS | WOOLWINE, SAMUEL C | — |
| 18270429 | COMPOUNDS, KITS, AND METHODS FOR BEAD-BASED DETECTION OF ANTI-MICROBE ANTIBODIES | CHEONG, CHEOM-GIL | — |
| 17201469 | METHOD FOR DETECTING CYSTIC FIBROSIS | SITTON, JEHANNE SOUAYA | — |
| Art Unit | Apps |
|---|---|
| 1681 | 2 |
| 1758 | 1 |
| 1645 | 1 |
| 1678 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19462819 | MASS SPECTROMETRY OF STEROIDAL COMPOUNDS IN MULTIPLEX SAMPLES | FRITCHMAN, REBECCA M | 1758 | §103 | Final Rejection | — | Pending | Jan 28, 2026 |
| 18884490 | MASS SPECTROMETRY METHOD FOR MEASURING THIAMINE IN BODY FLUID | SINGH, SATYENDRA K | — | §103§112DP | Non-Final OA | — | Pending | Sep 13, 2024 |
| 18794356 | METHODS FOR THE DIAGNOSIS OF BACTERIAL VAGINOSIS | WOOLWINE, SAMUEL C | 1681 | §103 | Final Rejection | — | Pending | Aug 05, 2024 |
| 18270429 | COMPOUNDS, KITS, AND METHODS FOR BEAD-BASED DETECTION OF ANTI-MICROBE ANTIBODIES | CHEONG, CHEOM-GIL | 1645 | §103 | Final Rejection | — | Pending | Jun 29, 2023 |
| 17986339 | BORDETELLA DETECTION ASSAY | BERTAGNA, ANGELA MARIE | 1681 | §112 | Final Rejection | 20d | Pending | Nov 14, 2022 |
| 17610044 | MULTIPLEX ASSAY FOR DETERMINING THE ß-AMYLOID 42/40 RATIO IN HUMAN PLASMA SPECIMENS | IVICH, FERNANDO NMN | 1678 | §101§103 | Non-Final OA | 22d overdue | Pending | Nov 09, 2021 |
| 17201469 | METHOD FOR DETECTING CYSTIC FIBROSIS | SITTON, JEHANNE SOUAYA | 1682 | §103 | Final Rejection | — | Pending | Mar 15, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial